Veerle Van Eygen

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · The Lancet · 2020 · 364 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Amy Cutrell, Jonathan Schapiro, Carlo Federico Perno et al. · AIDS · 2021 · 201 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

Chloe Orkin, Shinichi Oka, Patrick Philibert et al. · The Lancet HIV · 2021 · 177 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies

L Rimsky, Johan Vingerhoets, Veerle Van Eygen et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2011 · 175 citations

Life Sciences, Infectious Diseases, Pharmacotherapy +14

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Giuliano Rizzardini, Edgar T. Overton, Chloe Orkin et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2020 · 149 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17